|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 8.01 |
Other Events.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
Aquestive Therapeutics Press Release dated January 6, 2023.
|
Dated: January 23, 2023
|
Aquestive Therapeutics, Inc.
|
||
By:
|
/s/ A. Ernest Toth, Jr | ||
Name:
|
A. Ernest Toth, Jr.
|
||
Title:
|
Chief Financial Officer
|
||
(Principal Financial Officer)
|